RecruitingNCT07252687

The Effect of Gender-affirmative Measures on Breast Perception in Trans Men

The Effect of Gender-affirmative Measures on Breast Perception in Trans Men (TRANSBREAST) - a Prospective Cohort Study


Sponsor

Medical University Innsbruck

Enrollment

100 participants

Start Date

Nov 30, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

Breast dysphoria in transmasculine or genderdiverse individuals is a distinct psychological burden associated with depression, anxiety and suicidality. The aim is to systematically investigate the effect of GAHT (gender-affirming hormone therapy) and mastectomy on this form of dysphoria. The primary objective of this study is to analyse and investigate the psychological and physical effects of breast development on trans men or genderdiverse individuals. A secondary objective is to determine the extent to which the stress affects the well-being of trans men depending on the coping strategies used (binding vs. taping).


Eligibility

Sex: FEMALEMin Age: 16 Years

Inclusion Criteria3

  • AFAB (Assigned Female At Birth)
  • before starting GAHT
  • before mastectomy

Exclusion Criteria4

  • Ongoing GAHT
  • Mastectomy already performed
  • Lack of capacity to give consent
  • Insufficient knowledge of German

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERquality of life questionnaire- iTransQoL, chest dysphoria measure

Before starting treatment, participants should complete the Chest Dysphoria Measure and iTransQoL questionnaires (=time point 0). The second time point for completing the questionnaires again is 3 months after starting hormone therapy. Subsequently, the questionnaires should be completed a third time after breast-affirming surgery. The final survey takes place two years after time point 0, or 6 months after the previous survey.


Locations(1)

Medical University Innsbruck

Innsbruck, Austria

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07252687


Related Trials